Matriptase: A culprit in cancer?

Future Oncology

Volumn 5, Issue 1, 2009, Pages 97-104

  List, Karin ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Carcinogenesis; HAI 1; Matriptase; Pericellular proteolysis; Proteases; Type II transmembrane serine protease family

Indexed keywords

MATRIPTASE; SCATTER FACTOR; SERINE PROTEINASE;

BREAST CANCER; CANCER GENETICS; CARCINOGENESIS; CELL SURFACE; COLORECTAL CANCER; GENE EXPRESSION PROFILING; GENE MUTATION; HOMEOSTASIS; HUMAN; MESOTHELIOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; UTERINE CERVIX CANCER; ANIMAL; ENZYMOLOGY; METABOLISM; NEOPLASM;

ANIMALS; HUMANS; NEOPLASMS; SERINE ENDOPEPTIDASES;

EID: 65349100027     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.1.97     Document Type: Review

References (62)

1. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB: Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast-cancer cells. Cancer Res. 53, 1409-1415 (1993).
2. Kim MG, Chen C, Lyu MS et al.: Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse Type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49, 420-428 (1999),
3. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB: Molecular cloning of cDNA for matriptase, a matrix-degrading scrine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236 (1999).
4. Takeuchi T, Shuman MA, Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl Acad. Sci. USA 96, 11054-11061 (1999).
5. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ: Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 22, 104-114 (2001).
6. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275, 26333-26342 (2000).
7. Bugge TH, List K, Szabo R: Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front. Biosci, 12, 5060-5070 (2007).
8. Wu Q. Type II transmembrane serine proteases. Curr. Top. Dev. Biol. 54, 167-206 (2003).
9. Hooper JD, Clements JA, Quigley JP, Antalis TM: Type II transmembrane serine proteases - insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276, 857-860 (2001).
10. Szabo R, Bugge TH: Type II transmembrane serine proteases in development and disease. Int. J. Biochem. Cell Biol. 40, 1297-1316 (2008).
11. Szabo R, Molinolo A, List K, Bugge TH: Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 26, 1546-1556 (2007).
12. Netzel-Arnett S, Currie BM, Szabo R et al.: Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J. Biol. Chem. 281, 32941-32945 (2006).
13. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH: Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am. J. Pathol. 168, 1513-1525 (2006).
14. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY: Characterization of matriptase expression in normal human tissues. J. Histochem. Cytochem. 51, 1017-1025 (2003).
15. List K, Hobson JP, Molinolo A, Bugge TH: Co-localization of the channel activating protease prostasin/(CAPI/PRSS8) with its candidate activator, matriptase. J. Cell. Physiol. 213, 237-245 (2007).
16. Seitz I, Hess S, Schulz H et al.: Membrane-type serine protease-1/ matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 769-775 (2007).
17. Tseng IC, Chou FP, Su SF et al.: Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. Am. J. Physiol. Cell Physiol. 295, C423-C431 (2008).
18. Kilpatrick LM, Harris RL, Owen KA et al.: Initiation of plasminogen activation on the surface of monocytes expressing the Type II transmembrane serine protease matriptase. Blood 108, 2616-2623 (2006).
19. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS: Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc. Natl Acad. Sci. USA 104, 5771-5776 (2007).
20. Cheng MF, Jin JS, Wu HW, Chiang PC, Sheu LF, Lee HS: Matriptase expression in the normal and neoplastic mast cells. Eur. J. Dermatol. 17, 375-380 (2007).
21. List K, Haudenschild CC, Szabo R et al.: Marriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-3779 (2002).
22. List K, Szabo R, Wertz PW et al.: Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 163, 901-910 (2003).
23. Alef T, Torres S, Hausser I, Metze D, Türsen U, Lestringant GG, Hénnies HC: Iclithyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J. Invest. Dermatol. DOI 10.1038/ jid.2008,311 (2008) (Epub ahead of print).
24. Mildner M, Ballaun C, Stichenwirth M et al.: Gene silencing in a human organotypic skin model. Biochem. Biophys. Res. Commun, 348, 76-82 (2006).
25. Avrahami L, Maas S, Pasmanik-Chor M et al.: Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype. Clin. Genet. 74, 47-53 (2008).
26. Basel-Vanagaite L, Attia R, Ishida-Yamamoto A et al.: Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding Type II transmembrane serine protease matriptase. Am. J. Hum. Genet. 80, 467-477 (2007).
27. List K, Currie B, Scharschmidt TC et al.: Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J. Biol. Chem. 282, 6714-6723 (2007).
28. Lee MS, Tseng IC, Wang Y et al.: Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. Am. J. Physiol. Cell Physiol. 293, C95-C105 (2007).
29. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY: The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J. Biol. Chem. 278, 26773-26779 (2003).
30. Kojima K, Tsuzuki S, Fushiki T, Inouye K: Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase. J. Biol. Chem. 283, 2478-2487 (2008).
31. Lee MS, Kiyomiya K, Benaud C, Dickson RB, Lin CY: Simultaneous activation and hepatocyce growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am. J. Physiol. Cell Physiol. 288, C932-C941 (2005).
32. Carney TJ, von der Hardt S, Sonntag C et al.: Inactivation of serine protease matriptase la by its inhibitor Hail is required for epithelia integrity of the zebrafish epidermis. Development 134, 3461-3471 (2007).
33. Mathias JR, Dodd ME, Walters KB et al.: Live imaging of chronic inflammation caused by mutation of zebrafish Hail. J. Cell Sci. 120, 3372-3383 (2007).
34. Fan B, Brennan J, Grant D, Peale F, Rangell L, Kirchhofer D: Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev. Biol. 303, 222-230 (2007).
35. Nagaike K, Kawaguchi M, Takeda N et al.: Defect of hepatocyte growth factor activator inhibitor Type 1/serine protease inhibitor, Kunitz Type 1 (Hai-1/Spint1) leads to Ichthyosis-like condition and abnormal hair development in mice. Am. J. Pathol. 173, 1464-1475 (2008).
36. Szabo R, Hobson JP, List K, Molinola A, Lin CY, Bugge TH: Potent inhibition and global co-localization implicate the transmembrane kunitz-type serine protease-inhibitor hai-2 in the regulation of epithelial matriptase activity. J. Biol. Chem. 283(43), 29495-29504 (2008).
37. Lee SL, Dickson RB, Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720-36725 (2000).
38. Suzuki M, Kobayashi H, Kanayama N et al.: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J. Biol. Chem. 279, 14899-14908 (2004).
39. Förbs D, Thiel S, Stella MC et al.: In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol. 27, 1061-1070 (2005).
40. Ahmed S, Jin X, Yagi M et al.: Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J. 273, 615-627 (2006).
41. Darragh MR, Bhatt AS, Craik CS: MT-SP1 proteolysis and regulation of cell- microenvironment interactions. Front. Biosci. 13, 528-539 (2008).
42. Shipway A, Danahay H, Williams JA, Tully DC, Backes BJ, Harris JL: Biochemical characterization of prostasin, a channel activating protease. Biochem. Biophys. Res. Commun. 324, 953-963 (2004).
43. Leyvraz C, Charles RP, Rubera I et al.: The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J. Cell Biol. 170, 487-496 (2005).
44. Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS: Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray-analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 49, 388-395 (2006).
45. Riddick ACP, Shukla CJ, Pennington CJ et al.: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 92, 2171-2180 (2005).
46. Hoang CD, D'Cunha J, Kratzke MG et al.: Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125, 1843-1852 (2004).
47. Tsai WC, Chu CH, Yu CP et al.: Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters: Dis. Markers 24, 89-99 (2008).
48. Cheng MF, Tzao C, Tsai WC et al.: Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis. Esophagus 19, 482-486 (2006).
49. Saleem. M, Adhami VM, Zhong W et al.: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol. Biomarkers Prev. 15, 217-227 (2006).
50. Lee JW, Song SY, Choi JJ et al.: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum. Pathol. 36, 626-633 (2005).
51. Tanimoto H, Shigemasa K, Tian X et al.: Transmembrane serine protease TADG-15 (ST14/matriptase/MT-SPI): expression and prognostic value in ovarian cancer. Br. J. Cancer 92, 278-283 (2005).
52. Santin AD, Cane' S, Bellone S et al.: The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/- MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 98, 1898-1904 (2003).
53. Kang JY, Dolled-Filhart M, Ocal IT et al.: Tissue microarray analysis of hepatocyte growth factor/Met pathway components. reveals a role for Men matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63, 1101-1105 (2003).
54. Oberst MD, Johnson MD, Dickson RB et al.: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8, 1101-11017 (2002).
55. Jin JS, Cheng TF, Tsai WC, Sheu LF, Chiang H, Yu CP: Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol. Histopathol. 22, 305-309 (2007).
56. Warren M, Twohig M, Pier T et al.: Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl. Immunohistochem. Mol. Morphol. 17(1), 23-30 (2008).
57. Vogel LK, Saebo M, Skielbred CF et al.: The ratio of Matriptase/ HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 6, 176 (2006).
58. Galkin AV, Mullen L, Fox WD et al.: CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 61, 228-235 (2004).
59. Sanders AJ, Parr C, Davies G et al.: Genetic reduction of matriptase-I expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. J. Exp. Ther. Oncol. 6, 39-48 (2006).
60. Sanders AJ, Parr C, Mason MD, Jiang WG: Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int. J. Mol. Med. 20, 613-619 (2007).
61. Parr C, Jiang WG: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int. J. Cancer 119, 1176-1183 (2006).
62. List K, Szabo R, Molinolo A et al.: Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes. Dev. 19, 1934-1950 (2005).